Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 2
1965 2
1967 3
1969 3
1970 3
1971 1
1975 1
1976 2
1979 2
1980 1
1981 3
1982 4
1983 6
1984 3
1985 3
1986 2
1988 1
1989 3
1990 4
1991 6
1992 3
1993 2
1994 3
1995 1
1996 4
1997 2
1998 1
1999 3
2000 1
2001 1
2003 1
2004 3
2005 3
2006 5
2007 4
2008 8
2009 5
2010 4
2011 5
2012 3
2013 1
2014 4
2015 1
2016 4
2017 4
2018 1
2019 3
2020 2
2021 5
2022 8
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for Daniel F. cancer
Your search for Daniel F. Caner retrieved no results
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
Tomás CC, Oliveira E, Sousa D, Uba-Chupel M, Furtado G, Rocha C, Teixeira A, Ferreira P, Alves C, Gisin S, Catarino E, Carvalho N, Coucelo T, Bonfim L, Silva C, Franco D, González JA, Jardim HG, Silva R, Baixinho CL, Presado MªH, Marques MªF, Cardoso ME, Cunha M, Mendes J, Xavier A, Galhardo A, Couto M, Frade JG, Nunes C, Mesquita JR, Nascimento MS, Gonçalves G, Castro C, Mártires A, Monteiro MªJ, Rainho C, Caballero FP, Monago FM, Guerrero JT, Monago RM, Trigo AP, Gutierrez ML, Milanés GM, Reina MG, Villanueva AG, Piñero AS, Aliseda IR, Ramirez FB, Ribeiro A, Quelhas A, Manso C, Caballero FP, Guerrero JT, Monago FM, Santos RB, Jimenez NR, Nuñez CG, Gomez IR, Fernandez MªJL, Marquez LA, Moreno AL, Huertas MªJT, Ramirez FB, Seabra D, Salvador MªC, Braga L, Parreira P, Salgueiro-Oliveira A, Arreguy-Sena C, Oliveira BF, Henriques MªA, Santos J, Lebre S, Marques A, Festas C, Rodrigues S, Ribeiro A, Lumini J, Figueiredo AG, Hernandez-Martinez FJ, Campi L, Quintana-Montesdeoca MªP, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Parente A, Mata MªA, Pereira AMª, Fernandes A, Brás M, Pinto MªR, Parreira P, Basto ML, Rei AC, Mónico LM, Sousa G, Morna C, Freitas O, Freitas G, Jardim A, Vasconcelos … See abstract for full author list ➔ Tomás CC, et al. Among authors: daniel f. BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5. BMC Health Serv Res. 2016. PMID: 27409075 Free PMC article.
Martins O179 Women's beliefs about pap smear test and cervical cancer: influence of social determinants Ana B Pinheiro, Priscila S. ...Castuera, Helena Mesquita, Antonio Faustino, Jorge Santos, Samuel Honorio O200 Therapeutic itinerary of women with breast cancer in …
Martins O179 Women's beliefs about pap smear test and cervical cancer: influence of social determinants Ana B Pinheiro, Priscila S. . …
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Cunningham D, et al. Among authors: daniel f. N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149. N Engl J Med. 2008. PMID: 18172173 Free article. Clinical Trial.
BACKGROUND: We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer. METHODS: In a two-by-two design, we randomly assigned …
BACKGROUND: We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorourac …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Sartore-Bianchi A, et al. Among authors: daniel f. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1. Nat Med. 2022. PMID: 35915157 Free PMC article. Clinical Trial.
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. ...
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorecta …
2023 Canadian Surgery Forum: Sept. 20-23, 2023.
Brière R, Émond M, Benhamed A, Blanchard PG, Drolet S, Habashi R, Golbon B, Shellenberger J, Pasternak J, Merchant S, Shellenberger J, La J, Sawhney M, Brogly S, Cadili L, Horkoff M, Ainslie S, Demetrick J, Chai B, Wiseman K, Hwang H, Alhumoud Z, Salem A, Lau R, Aw K, Nessim C, Gawad N, Alibhai K, Towaij C, Doan D, Raîche I, Valji R, Turner S, Balmes PN, Hwang H, Hameed SM, Tan JGK, Wijesuriya R, Tan JGK, Hew NLC, Wijesuriya R, Lund M, Hawel J, Gregor J, Leslie K, Lenet T, McIsaac D, Hallet J, Jerath A, Lalu M, Nicholls S, Presseau J, Tinmouth A, Verret M, Wherrett C, Fergusson D, Martel G, Sharma S, McKechnie T, Talwar G, Patel J, Heimann L, Doumouras A, Hong D, Eskicioglu C, Wang C, Guo M, Huang L, Sun S, Davis N, Wang J, Skulsky S, Sikora L, Raîche I, Son HJ, Gee D, Gomez D, Jung J, Selvam R, Seguin N, Zhang L, Lacaille-Ranger A, Sikora L, McIsaac D, Moloo H, Follett A, Holly, Organ M, Pace D, Balvardi S, Kaneva P, Semsar-Kazerooni K, Mueller C, Vassiliou M, Al Mahroos M, Fiore JF Jr, Schwartzman K, Feldman L, Guo M, Karimuddin A, Liu GP, Crump T, Sutherland J, Hickey K, Bonisteel EM, Umali J, Dogar I, Warden G, Boone D, Mathieson A, Hogan M, Pace D, Seguin N, Moloo H, Li Y, Be… See abstract for full author list ➔ Brière R, et al. Among authors: daniel f. Can J Surg. 2023 Dec 13;66(6 Suppl 1):S54-S136. doi: 10.1503/cjs.014223. Print 2023 Nov-Dec. Can J Surg. 2023. PMID: 38173057 Free PMC article. No abstract available.
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
ASTEC study group; Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. ASTEC study group, et al. Lancet. 2009 Jan 10;373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3. Epub 2008 Dec 16. Lancet. 2009. PMID: 19070889 Free PMC article. Clinical Trial.
BACKGROUND: Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial cancer. Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a therapeutic procedure; however, randomise …
BACKGROUND: Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial cancer. Systematic …
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2012 Jul 11;308(2):147-56. doi: 10.1001/jama.2012.7352. JAMA. 2012. PMID: 22782416 Clinical Trial.
Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. ...DESIGN, SETTING, AND PATIENTS: The European Study Group for Pancreatic Cancer (ESPAC)-3 periamp …
Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials …
Ramucirumab: the long and winding road toward being an option for mCRC treatment.
Debeuckelaere C, Murgioni S, Lonardi S, Girardi N, Alberti G, Fano C, Gallimberti S, Magro C, Ahcene-Djaballah S, Daniel F, Fassan M, Prenen H, Loupakis F. Debeuckelaere C, et al. Among authors: daniel f. Expert Opin Biol Ther. 2019 May;19(5):399-409. doi: 10.1080/14712598.2019.1600505. Epub 2019 Apr 16. Expert Opin Biol Ther. 2019. PMID: 30917706 Review.
INTRODUCTION: Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality worldwide. ...
INTRODUCTION: Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality worldwide. ...
Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis.
Chrun ES, Modolo F, Daniel FI. Chrun ES, et al. Among authors: daniel fi. Pathol Res Pract. 2017 Nov;213(11):1329-1339. doi: 10.1016/j.prp.2017.06.013. Epub 2017 Jun 28. Pathol Res Pract. 2017. PMID: 28882400 Review.
In this review, we analysed studies reporting the process of histone modification, the enzymes associated and affected genes concerning human malignancies and histone enzyme inhibitor drugs used in cancer treatment. Variable degrees of expression of HDACs (histone deacetyl …
In this review, we analysed studies reporting the process of histone modification, the enzymes associated and affected genes concerning huma …
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Boccaccino A, Rossini D, Raimondi A, Carullo M, Lonardi S, Morano F, Santini D, Tomasello G, Niger M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, Palermo F, Pietrantonio F, Cremolini C. Boccaccino A, et al. Among authors: daniel f. Eur J Cancer. 2023 Aug;189:112910. doi: 10.1016/j.ejca.2023.05.001. Epub 2023 May 6. Eur J Cancer. 2023. PMID: 37301718 Clinical Trial.
A new approach to AEs evaluation, taking into account chronic low-grade AEs, single patient's perspective, and time-related information, such as ToxT analysis, should be considered especially for less intense but potentially long-lasting treatments, such as maintenance strategies …
A new approach to AEs evaluation, taking into account chronic low-grade AEs, single patient's perspective, and time-related information, suc …
147 results